The treatment of polycythaemia vera: An update in the JAK2 era

Internal and Emergency Medicine

Volumn 2, Issue 1, 2007, Pages 13-18

  Finazzi, G ^a   Barbui, T ^a  

^a OSPEDALI RIUNITI   (Italy)

Author keywords

Aspirin; Hydroxyurea; Interferon; JAK 2 mutation; Phlebotomy

Indexed keywords

JAK2 PROTEIN, HUMAN; JANUS KINASE 2; UNCLASSIFIED DRUG;

GENETICS; HUMAN; MUTATION; POLYCYTHEMIA VERA; REVIEW;

HUMANS; JANUS KINASE 2; MUTATION; POLYCYTHEMIA VERA;

EID: 34249911989     PISSN: 18280447     EISSN: 19709366     Source Type: Journal    
DOI: 10.1007/s11739-007-0003-4     Document Type: Review

References (33)

1. Schafer AI (2006) Molecular basis of the diagnosis and treatment of polycythemia vera and essential thrombocythemia. Blood 107:4214-4222
2. Finazzi G, Barbui T (2005) Risk-adapted therapy in essential thrombocythemia and polycythemia vera. Blood Rev 19:243-252
3. Berk PD, Goldberg JD, Donovan PB et al (1986) Therapeutic recommendations in polycythemia vera based on Polycythemia Vera Study Group protocols. Semin Hematol 23:132-143
4. Fruchtman SM, Mack K, Kaplan ME et al (1997) From efficacy to safety: a polycythemia vera study group report on hydroxyurea in patients with polycythemia vera. Semin Hematol 34:17
5. Marchioli R, Finazzi G, Landolfi R et al (2005) Vascular and neoplastic risk in a large cohort of patients with polycythemia vera. J Clin Oncol 23:2224-2232
6. Tartaglia AP, Goldberg JD, Berk PD et al (1986) Adverse effects of antiaggregating platelet therapy in the treatment of polycythemia vera. Semin Hematol 23:172-176
7. Streiff MB, Smith B, Spivak JL (2002) The diagnosis and management of polycythemia vera in the era since the Polycythemia Vera Study Group: a survey of the American Society of Hematology members' practice patterns. Blood 99:1144-1149
8. Landolfi R, Marchioli R, Kutti J et al (2004) Efficacy and safety of low-dose aspirin in polycythemia vera. N Engl J Med 350:114-124
9. Van Genderen PJJ, Prins F, Michiels JJ et al (1999) Thromboxane-dependent platelet activation in vivo precedes arterial thrombosis in thrombocythaemia: a rationale for the use of low-dose aspirin as an antithrombotic agent. Br J Haematol 104:438-441
10. Pearson TC, Wetherley-Mein G (1978) Vascular occlusive episodes and venous haematocrit in primary proliferative polycythaemia. Lancet 2:1219-1222
11. Patrono C, Garcia-Rodriguez LA, Landolfi R et al (2005) Low-dose aspirin for the prevention of atherothrombosis. N Engl J Med 353:2373-2383
12. Nand S, Stock W, Godwin J et al (1996) Leukemogenic risk of hydroxyurea therapy in polycythemia vera, essential thrombocythemia and myeloid metaplasia with myelofibrosis. Am J Hematol 52:42-46
13. Sterkers Y, Preudhomme C, Lai J-L et al (1998) Acute myeloid leukemia and myelodyslastic syndromes following essential thrombocythemia treated with hydroxyurea: high proportion of cases with 17p deletion. Blood 91:616-622
14. Hanft VN, Fruchtman SR, Pickens CV et al (2000) Acquired DNA mutations associated with in vivo hydroxyurea exposure. Blood 95:3589-3593
15. Marchioli R, Finazzi G, Marfisi RM et al (2005) Clinical trials in myeloproliferative disorders: looking forward. Semin Hematol 42:259-265
16. Finazzi G, Caruso V, Marchioli R et al (2005) Acute leukemia in polycythemia vera. An analysis of 1,638 patients enrolled in a prospective observational study. Blood 105:2664-2670
17. Finazzi G, Ruggeri M, Rodeghiero F et al (2000) Second malignancies in patients with essential thrombocythemia treated with busulphan and hydroxyurea: long-term follow-up of a randomized clinical trial. Br J Haematol 110:577-583
18. Silver RT (1993) Interferon alpha2b: a new treatment for polycythemia vera. Ann Intern Med 119:1091-1092
19. Martyre MC (2003) Critical review of pathogenetic mechanisms in myelofibrosis with myeloid metaplasia. Curr Hematol Rep 2:257-263
20. Lengfelder E, Berger U, Hehlmann R (2000) Interferon alpha in the treatment of polycythemia vera. Ann Hematol 79:103-109
21. Heis N, Rintelen C, Gisslinger B et al (1999) The effect of interferon alpha on myeloproliferation and vascular complications in polycythemia vera. Eur J Haematol 62:27-31
22. Gilbert HS (1998) Long term treatment of myeloproliferative disease with interferon alpha-2b: feasibility and efficacy. Cancer 83:1205-1213
23. Silver RT (2006) Long-term effects of the treatment of polycythemia vera with recombinant interferon-alpha. Cancer 107:451-458
24. James C, Ugo V, Le Couedic JP et al (2005) A unique clonal JAK2 mutation leading to constitutive signaling causes polycythemia vera. Nature 434:1144-1148
25. Levine RL, Wadleigh M, Cools J et al (2005) Activating mutation of the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 7:387-397
26. Baxter EJ, Scott LM, Campbell PJ et al (2005) Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative diseases. Lancet 365:1054-1061
27. Kralovics R, Passamonti F, Buser AS et al (2005) A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 352:1779-1790
28. Zhao R, Xing S, Li Z et al (2005) Identification of an acquired JAK2 mutation in polycythemia vera. J Biol Chem 280:22788-22792
29. Jones AV, Kreil S, Zoi K et al (2005) Widespread occurrence of the JAK2 V617 mutation in chronic myeloproliferative disorders. Blood 106:2162-2168
30. Kaushansky K (2005) On the molecular origin of the chronic myeloproliferative disorders: it all makes sense. Blood 105:4187-4190
31. Silver RT, Fruchtman SM, Feldman EJ et al (2004) Imatinib mesylate (Gleevec) is effective in the treatment of polycythemia vera: a multi-institutional clinical trial. Blood 104:189a
32. Jones AV, Silver RT, Waghorn K et al (2006) Minimal molecular response in polycythemia vera patients treated with imatinib or with Interferon alpha. Blood 107:3339-3341
33. Kiladjian JJ, Cassinat B, Turlure P et al (2006) High molecular response rate of polycythemia vera patients treated with pegylated Interferon alpha-2a. Blood 108:2037-2040